Blog
26 March 2015
Crossing the Blood-Brain Barrier: Profiling Cognitive Safety in Clinical Development
The blood-brain barrier (BBB) is a highly regulated and complex layer of cells that has evolved to protect the brain from toxic molecules and infectious agents. Dr Kenton Zavitz, Director of Clinical Affairs explores the crossing of the blood-brain barrier and how to measure and monitor the cognitive effects of drug compounds in clinical trials.
Read on
25 March 2015
Should the FDA revoke approvals for non-abuse deterrent generic opioids?
Scientist and Product Specialist Linda Hermans explores whether the FDA should revoke approvals for non-abuse deterrent generic opioids.
Read on
24 March 2015
Pharmacy scheme raises dementia diagnosis rates
A small-scale evaluation project has demonstrated the value of using in-pharmacy Cantab Mobile assessments to help identify patients that might otherwise be missed.
Read on
24 March 2015
Early dementia diagnosis gives patients more options
Doncaster CCG improve dementia diagnosis rates through the use of Cantab Mobile.
Read on
13 March 2015
Characterization Of Cognitive Decline Over 5 Years in an Incident Parkinson’s Disease Cohort
Pradeep Nathan, PhD, Senior Scientific Director presented a poster at ADPD 2015 on the Characterization Of Cognitive Decline Over 5 Years in an Incident Parkinson’s Disease Cohort, view the poster here.
Read on
12 March 2015
The use of CANTAB and language tests in healthy and pathological aging
'CANTAB and language tests to search for the limits between normal and pathological aging' was recently inducted into the Cantab Bibliography, corresponding author Cristovam W Picanço Diniz explains more about the research study.
